Evidence map›Paper›PMID 39200727›Full record

ArticleJournal of clinical medicine2024

Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer.

Oğuzcan Kınıkoğlu, Bala Başak Öven, Serkan Çelik, Nalan Alan Selçuk, Gamze Beydağı, Kaan Akçay, Levent Kabasakal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Combination therapy strategies in engineeredCell communication and signaling : CCS · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Oğuzcan KınıkoğluDepartment of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, İstanbul 34865, Türkiye.ORCID 0000-0001-5983-3291
Bala Başak ÖvenDepartment of Medical Oncology, Yeditepe University Medical Faculty, İstanbul 34718, Türkiye.ORCID 0000-0002-9921-4089
Serkan ÇelikDepartment of Medical Oncology, Yeditepe University Medical Faculty, İstanbul 34718, Türkiye.
Nalan Alan SelçukDepartment of Nuclear Medicine, Yeditepe University Medical Faculty, İstanbul 34718, Türkiye.
Gamze BeydağıDepartment of Nuclear Medicine, Yeditepe University Medical Faculty, İstanbul 34718, Türkiye.
Kaan AkçayDepartment of Nuclear Medicine, Yeditepe University Medical Faculty, İstanbul 34718, Türkiye.
Levent KabasakalDepartment of Nuclear Medicine, Istanbul University Cerrahpaşa Medical Faculty, İstanbul 34098, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

androgen receptor pathway inhibitorscombination therapyLutetium-177 PSMA-617 radioligand therapymetastatic castration-resistant prostate cancer

Identifiers

PMID39200727
PMCPMC11354391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.